Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Psychopharmacologic Drugs Advisory Committee

Executive Summary

Will meet July 19 to consider Bristol-Myers' NDA (20-152) for nefazodone and preclinical toxicity data "relevant to the risk benefit assessment" of Janssen's Risperdal (risperidone), a June 25 Federal Register notice states. Risperdal, (NDA 20-272), a dopamine and serotonin blocker, received a unanimous approval recommendation from the committee on April 29 ("The Pink Sheet" May 3, p. 12). The committee will meet July 20 to consider Lilly's NDA (20-187) for Prozac (fluoxetine) for use in the treatment of obsessive compulsive disorder. Meetings will begin both days at 8:30 a.m. in conference rooms D and E at FDA's Parklawn Building in Rockville, Md.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022847

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel